Saturday, June 6, 2026
1:00 – 3:00 p.m.
ESSENENTIAL3 PROGRAM TOPLINE RESULTS
presented by
Carol Clark, Head of Marketing and
Monique Giroux, Executive Medical Director
Praxis Precision Medicines
Meeting Location:
The Hospital of Central Connecticut
100 Grand Street, New Britain, CT 06050
In a December 29, 2025 press release, Praxis Precision Medicines announced the FDA granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor. The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential tremor.
In a press release dated April 14, 2026, Praxis Precision Medicines announced FDA acceptance of the New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor.
You won’t want to miss our June 6th meeting. This presentation shares topline results from Essential3, an at-home research study!
Dr. Monique L. Giroux is a board-certified neurologist and fellowship-trained movement disorders specialist, clinical researcher with over two decades of experience caring for people living with Parkinson’s disease, essential tremor, and related conditions. She has dedicated her career to improving quality of life through patient-centered, interdisciplinary care, combining clinical expertise with a deep commitment to research, education, empowerment, and community support.
Dr. Giroux currently serves as Executive Director of Clinical Development at Praxis Precision Medicines, where she leads clinical oversight of research programs including the recent phase 3 trials evaluating ulixacaltamide as a treatment for essential tremor and other movement disorders.
Inquiries are invited!
Registration is required no later than
5:00 p.m. on Wednesday, June 3rd!
To register or request information,
submit the form below:
The CT essential tremor support group is sponsored by
